Smoking Cessation for Patients With Cancer: State of the Evidence
Date
2025-05-01
Authors
Journal Title
Journal ISSN
Volume Title
Citation Stats
Attention Stats
Abstract
Although it is generally well-known that smoking poses numerous risks to physical health and well-being, it carries additional risks for patients with cancer. Therefore, smoking cessation is of particular concern among this patient population. At the NCCN 2025 Annual Conference, a panel convened to discuss the current evidence surrounding smoking-associated risks for patients with cancer, the benefits of smoking cessation specific to them, and evidence-based approaches to improve rates of smoking cessation.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Davis, JM, D Edmondson, ME Reid and LJ Bierut (2025). Smoking Cessation for Patients With Cancer: State of the Evidence. Jnccn Journal of the National Comprehensive Cancer Network, 23(Supplement). 10.6004/jnccn.2025.5009 Retrieved from https://hdl.handle.net/10161/34762.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
James Davis
Dr. James Davis is a practicing physician of Internal Medicine, and serves as the Medical Director for Duke Center for Smoking Cessation, Director of the Duke Smoking Cessation Program and Co-Director of the Duke-UNC Tobacco Treatment Specialist Credentialing Program. His research focuses on development of new pharmaceutical treatments for smoking cessation. He is principal investigator on several trials including a study on “adaptive” smoking cessation and several trials on new medications for smoking cessation. The new medications leverage more novel neurobiological mechanisms - NMDA receptor antagonism, nicotinic receptor antagonism, which impact addiction-based learning and cue response. Additionally, Dr. Davis serves as co-investigator on trials on lung cancer screening, e-cigarettes, minor nicotine alkaloids, imaging trials, lung function trials and others. Dr. Davis leads the Duke Smoke-Free Policy Initiative, is co-author on a national tobacco dependence treatment guideline, and provides training in tobacco dependence treatment for the Duke School of Medicine, Duke Internal Medicine, Family Practice and Psychiatry residency programs.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.